Background Autoimmune neutropenia (AIN) is the main cause of chronic neutropenia in children, but its infectious consequences ...
Armlupeg, a biosimilar to Neulasta, is approved for reducing febrile neutropenia in non-myeloid malignancy patients undergoing myelosuppressive chemotherapy. Lupin's FDA-approved facility in India ...
Pegfilgrastim-unne is approved for patients with nonmyeloid cancer on myelosuppressive chemotherapy to reduce febrile neutropenia risk. The biosimilar is administered as a 6-mg/0.6-mL subcutaneous ...
Objectives This study aimed to investigate the knowledge, attitude and practice (KAP) towards chemotherapy-related neutropenia and febrile neutropenia (FN) among breast cancer patients. The major ...
Chemotherapy, a cornerstone of cancer treatment, often results in adverse events that carry significant physical, emotional, and economic repercussions. One particularly critical adverse event is ...
Investigators used a predictive model factoring in lymphopenia, elevated SIL2R level, extranodal involvement, and a positive hepatitis panel to determine risk for febrile neutropenia among patients ...
Neutropenia involves a low neutrophil count, and thrombocytopenia involves a low platelet count. Certain conditions, infections, or medications may cause reduced levels of both. Neutropenia and ...
The Food and Drug Administration approved Udenyca Onbody, an administration device for Udenyca, a biosimilar of Neulasta. The Food and Drug Administration (FDA) approved Udenyca Onbody, an injector ...
Neutropenic sepsis is a body-wide reaction that can occur when a person with an infection or injury also has a low level of immune cells called neutrophils. Neutropenic sepsis is a medical emergency ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback